Recently approved in Australia, Nolvadex is used to treat breast cancer in women. The medicine can be used to prevent and reduce the risk of breast cancer recurrence.

Nolvadex is an antitumor agent from the group of nonsteroidal antiestrogens. The main therapeutic effect of the active ingredient Tamoxifen is the blockage of the estrogen receptors, which play an important role in the pathogenesis of cancer.

The most important effect of Nolvadex is the antimetastatic effect of the antiestrogen. The drug helps to inhibit the growth and migration of cancer cells. As a result, the progression of cancer is significantly slowed down, and the cancer tumor regresses.

The drug is used not only as an antagonist to the carcinogenic effect of estrogens. Nolvadex has other antitumour effects:

• programs the process of cancer cells death (apoptosis);
• inhibits the production of enzymes that stimulate cancer cells growth;
• prevents the formation of microvessels in the structure of a cancerous tumor.

After oral administration, Nolvadex is well absorbed and has almost absolute bioavailability. Peak concentrations in blood plasma are reached in 4-7 hours after the ingestion. The initial half-life of Nolvadex is 7-14 hours. Subsequent terminal half-life lasts for about 1 week. Equilibrium blood plasma concentrations are achieved after 3-4 weeks of regular Nolvadex use.

In Australian pharmacies, you can buy a pack of 30 Nolvadex tablets. Each tablet contains 10 mg or 20 mg of the active ingredient Tamoxifen. If a woman does not have a doctor’s prescription, she can buy Nolvadex online without a prescription absolutely legally. You can pay for the medicine via many payment systems, including Paypal.

• The initial Nolvadex dose is 20 mg daily. If there is no cancer regression, Nolvadex dose can be increased to 40 mg per day. The use of the antitumor drug can last for 5 years.

The hormonal antitumor therapy with Nolvadex differs from other methods of cancer treatment. Unlike surgery, radiation and chemotherapy, Nolvadex contributes to the death of tumor cells without adversely affecting healthy body tissues.

Nolvadex was not the first Tamoxifen-based drug. The patent for the invention of a new medicine was obtained on September 13, 1962. The drug was developed by the chemist Dora Richardson and the biologist Arthur Walpole.

It was originally intended to use Tamoxifen as a contraceptive. But Arthur Walpole did not abandon attempts to prove the effectiveness of the drug in the treatment of cancer.

It took more than 10 years before the first Nolvadex precursors began to be used in clinical practice for the treatment of cancer. Under the guidance of Dr. Craig Jordan in 1973, clinical trials on the treatment of cancer tumors with Tamoxifen were successfully completed.

In 1973, the United Kingdom became the first country, in which Tamoxifen was approved for the treatment of breast cancer. Four years later, the antitumor drug was approved in the USA. In 1983, Tamoxifen was proven effective in the long-term treatment of oncological diseases.

On April 4, 2016, Nolvadex got a marketing authorization in Australia. On April 22 of the same year, the drug was included in the list of drugs of the Pharmaceutical Benefits Scheme (PBS). Thus, the insured patients could buy Nolvadex at a reduced price. The Australian antitumor drug supplier is the pharmaceutical company AstraZeneca.

Even before Nolvadex appeared on the Australian pharmaceutical market, women had the opportunity to take other antitumor Tamoxifen-based drugs: Genox, Tamosin, Oxifen, Tamoxen, Tamfen and Taxifen. However, Nolvadex remains the only drug in Australia, which received a state subsidy as a means to prevent breast cancer.

Australian pharmacies offer not only the trademarks of the antitumor drug. The medicine is available for sale under its non-proprietary name. The Australian suppliers of Nolvadex generics are such pharmaceutical companies, as Alphapharm, Aspen Pharma, Medis Pharma, Apotex, Sandoz and Amneal Pharma.

If a woman plans to travel abroad while using Nolvadex, she can take the medicine with her. Since Nolvadex is a drug, subsidized by the government’s PBS program, woman must present a declaration on the right to export medicines to the customs at the customs screening. The Declaration is available on the official website of the Australian Department of Human Services (DHS).

The extensive spectrum of Nolvadex targets determines the effectiveness of the antitumor drug in the treatment of breast cancer. The drug remains the main one in hormone therapy of patients of reproductive age.